復星醫藥AH股午後跌幅曾擴至7%-8% 調查復必泰疫苗產品包裝瑕疵原因
復星醫藥(02196.HK)調查復必泰疫苗產品包裝瑕疵原因,該股午後跌幅曾擴至7%低見31.75元,現造32.3元,跌5.4%,成交增至333萬股;其A股(600196.SH)午後股價跌幅曾擴至逾8%低見36.67元人民幣,現造37.65元人民幣,跌5.8%,成交3,175萬股。
復星醫藥公告指,昨晚接獲BioNTech書面通知,BioNTech注意到其生產供應香港與澳門批號為210102的復必泰疫苗產品中存在少量西林瓶封蓋有關瑕疵。為確保疫苗接種安全,BioNTech和集團已發起對該問題原因調查,並已通知港澳即日起暫停接種該批號復必泰疫苗,直至調查結束。此外,出於謹慎考慮,用於供應香港的批號為210104疫苗產品也將進行封存,直至另行通知。不過,截至本公告日,未有證據表明相關批次產品安全可能存在風險,具體情況以最終調查結果為準。該疫苗是次暫停使用並作封存,對於相關批次疫苗在香港、澳門的後續接種安排可能存在影響,具體以調查結果為準。不過,該疫苗是次暫停使用並作封存,預計不會對集團正常生產經營造成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.